MedTrace Logo

A Prospective Trial of COXEN Chemotherapy Prediction

NCT01228942 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2014-06-06

No results posted yet for this study

Summary

The purpose of this study is to determine if the COXEN algorithm, using the diagnostic device Affymetrix GeneChip, is able to predict which chemotherapies will be best for treatment of recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer.

Conditions

  • Ovarian Neoplasms
  • Fallopian Tube Neoplasms

Interventions

DEVICE

COXEN analysis for chemotherapy prediction

Using the affymetrix genechip along with the COXEN algorithm the subject's treatment will be determined

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Linda Duska, MD · University of Virginia

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-10-31
Completion
2013-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01228942 on ClinicalTrials.gov